Castle Biosciences' Cost of Revenue rose 1982.83% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.9 million, marking a year-over-year increase of 2205.86%. This contributed to the annual value of $60.2 million for FY2024, which is 3384.24% up from last year.
Castle Biosciences' Cost of Revenue amounted to $18.7 million in Q3 2025, which was up 1982.83% from $17.6 million recorded in Q2 2025.
Castle Biosciences' 5-year Cost of Revenue high stood at $18.7 million for Q3 2025, and its period low was $3.0 million during Q1 2021.
Moreover, its 5-year median value for Cost of Revenue was $11.1 million (2023), whereas its average is $10.8 million.
Per our database at Business Quant, Castle Biosciences' Cost of Revenue surged by 10789.83% in 2022 and then soared by 1791.42% in 2025.
Castle Biosciences' Cost of Revenue (Quarter) stood at $4.6 million in 2021, then soared by 107.09% to $9.5 million in 2022, then soared by 30.49% to $12.4 million in 2023, then surged by 30.27% to $16.2 million in 2024, then grew by 15.58% to $18.7 million in 2025.
Its Cost of Revenue stands at $18.7 million for Q3 2025, versus $17.6 million for Q2 2025 and $16.4 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value